IL2RA and acute myeloid leukemia: This result is consistent with previous observations that overexpression of IL2RA, for example, has been associated with chemotherapy resistance and poor prognosis in AML.[38] Hazard ratio analysis further identified C19ORF59 (MCEMP1) as a significant risk factor (HR = 0.50, 95% CI = 0.32–0.79, P = 0.0038; Figure 6B).